Thinking about switching from orlistat to Mounjaro? Here's what changes

You've hit the ceiling orlistat can reach, so what's actually different about Mounjaro?

Picture this: you've been taking three orlistat capsules a day for several months, you've adapted your diet to keep fat intake low enough to avoid side effects, and the scales haven't moved meaningfully in weeks. That's one of the most common situations our prescribers hear about. Orlistat works in the gut (it blocks roughly a third of dietary fat from being absorbed) but it doesn't touch appetite, hunger signals or the hormonal drivers of weight. The moment you stop taking it, nothing has changed in how your body regulates energy intake.

Mounjaro (tirzepatide, made by Eli Lilly) acts on two gut-hormone pathways simultaneously: GIP and GLP-1 receptors. Activating both slows gastric emptying, increases the sensation of fullness and reduces appetite at the brain level. The clinical-trial results reflect that difference. In SURMOUNT-1, published in the New England Journal of Medicine, adults without diabetes lost an average of around 20–21% of body weight over 72 weeks at the 15mg dose, figures no fat-absorption blocker has come close to. If you want to understand whether orlistat is genuinely better than Mounjaro for any particular situation, the differences in trial results are a useful starting point for that comparison. Orlistat trials have generally shown average weight loss in the range of 5–7% over one year alongside diet changes, which is clinically useful but substantially more modest.

The mechanism shift also changes what the medicine asks of you. Orlistat demands strict dietary fat restriction to remain tolerable; Mounjaro's adjustments are about eating alongside reduced appetite, with protein and hydration the main practical considerations. For many people, that's a more manageable ask, though nausea in the early weeks is real and worth knowing about before you start.

How do orlistat and Mounjaro compare on the details that matter?

The NICE appraisal of tirzepatide (TA1026) sets specific NHS eligibility criteria; private eligibility through a regulated pharmacy is broader, starting at BMI 30 or BMI 27 with a qualifying condition, assessed case by case. For a fuller breakdown of the two medicines' profiles, the orlistat vs Mounjaro comparison page goes into greater depth on mechanism and trial evidence.

Practical realities of making the switch

The most immediate practical difference: Mounjaro is an injection. Once weekly, subcutaneous, into the abdomen, thigh or upper arm. The pre-filled KwikPen is straightforward to use, and most people find the injection itself unremarkable after the first or second time. Storage requires a fridge, many people keep the pen in the fridge door, alongside everyday items, which doubles as a reminder. The pen in use can be kept at room temperature for a limited window; for the exact timeframe, the Mounjaro Patient Information Leaflet is the authority.

Treatment starts at 2.5mg, a starter dose designed to let your system adjust, and is titrated by your prescriber in steps (typically every four weeks) up to the dose that achieves the right balance of effect and tolerability for you. If you are switching from a GLP-1 medication to tirzepatide, the process differs slightly from coming off orlistat, but your prescriber will want to know what you've been taking, at what dose, for how long, and what results you've seen in either case. At nume, transfer patients provide evidence of current treatment before dose or medicine changes are approved; that's a safety step, not a bureaucratic one.

If the injection route is a consideration for you, it's worth knowing that some people who've been on orlistat for years find the once-weekly schedule considerably easier to manage than three daily capsules timed around meals. Others prefer the oral route. If that applies to you, our weight-loss treatment overview covers the options currently available, including Wegovy tablets, the first oral GLP-1 licensed in the UK for weight management.

Who can switch, and how the clinical assessment works at nume

Eligibility for Mounjaro in a private setting is assessed by a prescriber against the licensed criteria: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The fact that you've been on orlistat doesn't automatically qualify you, and it doesn't disqualify you either, what matters is the full clinical picture your prescriber sees.

At nume, that assessment happens through a free consultation reviewed the same working day. Our clinical team includes GPhC-registered Independent Prescribers who read every response personally; identity and weight are verified on video before any prescription is issued. If Mounjaro is suitable and approved before midday on a weekday, it's dispatched the same day and arrives with DPD the next working day. Answers to the questions that come up most often around eligibility and the consultation process are on our FAQs page.

If you're curious how Mounjaro sits relative to other injectable treatments you might be considering alongside this decision, the switching from Saxenda to Mounjaro page covers a parallel scenario. For people exploring what comes after Mounjaro in the pipeline, our page on switching from Mounjaro to retatrutide sets out how the two treatments differ and what the emerging evidence suggests, and if you want a broader look at how the two molecules compare, our breakdown of retatrutide vs Mounjaro covers the key differences in mechanism and trial data. The NHS medicines page on tirzepatide is also a useful plain-language reference for what to expect. Ultimately, which medicine is the right move for you is a decision made with your prescriber, not before you speak to one.